Edit
Morphotek, Inc.
http://www.morphotek.com/Last activity: 18.07.2021
Active - Reference to Eisai US
Morphotek is one of the leading companies in the life science industry that develops novel classes of biological-based products to treat cancer, inflammation and infectious diseases. Since its founding in 2000, Morphotek has made extraordinary progress in discovering and developing monoclonal antibodies (mABs) to treat these diseases and continues to develop additional antibody products using its proprietary technologies.
Location: United States, Pennsylvania, Exton
Employees: 51-200
Founded date: 2000
Investors 1
| Date | Name | Website |
| 18.07.2021 | Ben Frankl... | sep.benfra... |
Mentions in press and media 3
| Date | Title | Description |
| 17.09.2019 | Philadelphia Cancer-Fighting Biotech Startup Raises $3.2M | The convertible note financing was led by Ben Franklin Technology Partners of Southeastern Pennsylvania and a group of private investors. Navrogen plans to use the proceeds to advance its humoral immuno-oncology discovery platform and its p... |
| 13.09.2016 | Morphotek Announces Sponsored Research Agreement With Fox Chase Cancer Center To Study Immunosuppressive Effects Of Tumor Shed Antigens To Improve Future Patient Therapies | The collaboration will utilize primary human organoid cultures derived from various cancer types using optimized assays developed by ongoing research in the laboratory of Dr. Wafik El-Deiry, Deputy Cancer Center Director, Translational Res... |
| 10.11.2015 | Morphotek Announces A License Agreement With Blaze Bioscience, Inc. For The Development Of Novel Oncology Imaging Technology | Under the agreement, Morphotek provides to Blaze an exclusive, worldwide, royalty-bearing license to develop, license, and once approved, commercialize a potential tumor-targeting chlorotoxin derivative linked to a near-infrared diagnostic... |